What Targifor Treats: Main Uses and Benefits

This therapeutic area covers the use of the product to help manage generalized symptoms of exhaustion, physical weakness, and low energy levels—a condition commonly referred to as asthenia. The ingredients present in the product may be part of symptomatic management for symptoms that interfere with daily functioning, such as persistent fatigue. It is generally applied when symptoms create noticeable interference with daily stability, providing supportive symptomatic relief that assists with maintaining functional stability when symptoms are more noticeable.

The product is commonly used in contexts involving periods of increased physiological stress, such as recovery after an acute viral illness, convalescence, or during intense periods of intellectual or physical overexertion. The product is applied in addressing symptom clusters that may become disruptive, offering symptomatic relief that supports patients during episodes of heightened discomfort. This is relevant for managing symptoms that interfere with daily comfort, such as physical weakness and low endurance.

“The primary goal of supportive management is to ease the overall burden of symptoms and contribute to improved comfort during difficult episodes.”

---

Quick Fact: Relief for Functional Fatigue

The product is commonly used to help manage symptoms linked to temporary functional strain, supports general well-being during symptomatic phases.

Regulatory References

1. NIH National Library of Medicine

The eligibility for using products containing Arginine Aspartate (such as Targifor) is strictly defined by regulatory documents, which establish conditions for who can and who must not use the medicine.

---

Eligibility Map: Official Regulatory Information

Eligibility Status	Populations and Conditions	Classification as per Label
Allowed	Adults and adolescents over 12 years of age.	Approved Age Group
Contraindicated	Patients with known hypersensitivity to Arginine Aspartate or excipients. Women who are pregnant or breastfeeding (for specific high-dose oral formulations).	Absolute Prohibition
Conditional Use/Caution	Patients with severe renal (kidney) impairment or severe hepatic (liver) impairment. Individuals with diabetes or cystic fibrosis.	Special Precaution Required
Not Recommended	Children under 12 years of age (for certain formulations due to dosage). Patients with recent acute myocardial infarction (heart attack).	Use Restriction

---

Age-Related and Comorbidity Restrictions

Formal restrictions are often based on the medicine's metabolic component. For instance, caution is required in patients with severe kidney or liver impairment due to the potential risk of hyperkalemia (elevated potassium levels). Specific product labels also place use restrictions on the pediatric population, typically setting a minimum age of 12 years for authorized use.

Interactions with other medicines and products

Official regulatory information for Arginine Aspartate, the active ingredient in Targifor, focuses on pharmacodynamic interactions and electrolyte risks, rather than common enzyme-mediated (CYP450) or transporter-based interactions.

Interaction-Related Restrictions

Category	Interacting Products or Agents	Regulatory Caution
Cardiovascular	Nitrates (e.g., Nitroglycerin) and Antihypertensive Agents (e.g., ACE Inhibitors, ARBs)	Co-administration may result in an additive hypotensive effect, potentially causing blood pressure to drop too low. This applies also to Erectile Dysfunction Medications (e.g., Sildenafil).
Electrolyte Balance	Potassium-Sparing Diuretics (e.g., Amiloride, Spironolactone)	Official sources advise against use due to a documented risk of hyperkalemia (increased potassium levels).
Hemostasis	Anticoagulant and Antiplatelet drugs/supplements	Combination may potentiate effects that slow blood clotting, which may increase the risk of bleeding.
Metabolic	Diabetes Medications	Co-administration may affect blood sugar concentrations, requiring monitoring.

Population-Specific Interaction Notes

The risk of developing high potassium levels (hyperkalemia) is specifically noted to be increased when Arginine Aspartate is combined with potassium-sparing diuretics in individuals with kidney disease. Furthermore, one official monograph lists a caution against use following a recent heart attack.

How Targifor Works

Aspartate Arginine is metabolized to provide L-arginine, a conditionally essential amino acid. L-arginine serves as the primary substrate for Nitric Oxide Synthase (NOS), an enzyme that catalyzes the production of Nitric Oxide (NO), a gaseous signaling molecule. NO acts locally to modulate smooth muscle tone and blood flow. Additionally, L-arginine is a key intermediary in the urea cycle, participating in the conversion of ammonia to urea for systemic nitrogen homeostasis. The aspartate component is integrated into the metabolic pool, participating in various transamination reactions.

Ascorbic Acid (Vitamin C) functions as a critical aqueous-phase antioxidant, protecting biomolecules from damage by reactive oxygen species (ROS). Furthermore, it is an essential cofactor for several enzymes, including those involved in the hydroxylation of proline and lysine residues during collagen biosynthesis and enzymes participating in the synthesis of certain neurotransmitters and carnitine.

How to Use Targifor (L-Arginine L-Aspartate)

Targifor, a formulation containing the amino acid L-arginine and the amino acid derivative L-aspartate, is typically administered orally. L-Arginine is an amino acid that plays a role in the synthesis of proteins and is a precursor for nitric oxide, a molecule involved in vascular function and blood flow regulation. The standard route of administration is by mouth, generally in the form of tablets, capsules, or an oral solution/granules, depending on the specific product formulation.

Dosage and Administration

Dosage of L-arginine, the primary active component, can vary widely based on the specific health indication, patient age, and the concentration of the product. The common daily dosage range studied for L-arginine in adults is generally 6 to 30 grams (g) orally, typically divided into three smaller doses throughout the day to maximize absorption and reduce the potential for gastrointestinal side effects.

Dosage Factor	Administration Guideline
Timing	For optimal absorption, L-arginine supplements are often recommended to be taken between meals.
Maximum Dose	Doses exceeding 10 grams at a single time may cause gastrointestinal discomfort or diarrhea; the maximum daily dose should not be exceeded.

It is critical to follow the specific instructions and recommended dosage provided on the product label or, preferably, the regimen prescribed by a qualified healthcare professional. Do not exceed the suggested daily dose. If a dose is missed, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to compensate for a missed one. Consult a healthcare provider before initiating any L-arginine supplementation, particularly if you are taking medications for blood pressure, blood clotting, or diabetes, as interactions may occur.

Research Evidence / Overview of Studies for Targifor

Evidence for Use in General Physical Fatigue and Asthenia

Research exploring the properties of Arginine Aspartate has included Randomized Controlled Trials (RCTs), a standard type of research design, as well as shorter-term studies related to physical performance. This preparation was studied for the purpose of understanding its role in general physical exhaustion and weakness resulting from overexertion or stress. These trials were evaluated in populations including healthy adults experiencing general asthenia, as well as students under mental stress and male endurance athletes. The studies often monitored patient-reported outcomes describing perceived discomfort and outcomes related to systemic or metabolic parameters.

Findings describe patterns observed in the studies related to both subjective feelings of fatigue and objective measures of physical capability. However, findings related to some measures of peak physical performance, such as the time an athlete could sustain high-intensity exercise, were described as mixed across different study settings. Research reviews describe that the evidence quality varies across studies, and many are based on smaller patient cohorts. Long-term effects are not fully established, and this research only provides context but not individual predictions for how an individual might respond.

---

Evidence for Use in Convalescence and Post-Viral Fatigue

More recent research has explored the compound's use in the context of convalescence and conditions involving periods of heightened symptoms, such as persistent fatigue following a viral illness (including post-COVID-19 fatigue). Studies in this area have primarily been prospective observational studies or Randomized Controlled Trials (RCTs) that research examined patient groups experiencing post-viral symptoms.

Studies report that changes were observed in some studies regarding subjective fatigue scores and measures of physical capability. The data show patterns related to measured changes over defined time intervals. However, the compound was often studied for post-viral fatigue in combination with co-ingredients like Vitamin C. Because of the frequent use of combination supplements, the extent to which the observed changes are solely attributable to Arginine Aspartate is an area where certainty remains low.

---

What is Still Uncertain About the Research for Targifor

Research focusing on long-term data for Arginine Aspartate is currently limited, with most trials observing responses over defined time intervals of no more than a few months. Comparative evidence is lacking; research has not yet explored the compound's patterns relative to other supportive approaches. Data for certain groups, such as children, older adults, or pregnant populations, remain insufficient to draw conclusions about its role in these cohorts.

Key Studies & References

1. Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism - a randomized, double-blind, placebo-controlled study
2. Effects of the acute arginine aspartate supplement on the muscular fatigue in trained volunteers

Common questions about Targifor (FAQ)

---

Q: What does 'oral solution' mean when describing Targifor?

A: According to official product information, Targifor is available in several forms designed for oral use. These forms typically include effervescent tablets, a ready-to-use oral solution, or granules that must be dissolved in a liquid before being consumed.

Q: Is Targifor the same as other amino acid supplements?

A: Targifor is not a generic amino acid supplement, but a specific drug preparation. Its active ingredient is Arginine Aspartate, which is a specific, high-solubility salt compound formed by combining the amino acids L-Arginine and L-Aspartic Acid. This specific salt is described in official documentation as an Amino Acid Preparation and Metabolic Regulator.

Q: Is Targifor safe for older adults (seniors)?

A: Official documents indicate caution regarding the use of this product in adults older than 65 years of age without professional medical oversight. Regulatory information also notes that a potential risk following a recent heart attack has been particularly observed in older patient populations.

Q: How long can a person continue to use Targifor according to official guidance?

A: Official information notes that L-Arginine, the active component, is generally reviewed as possibly safe for short-term use. Regulatory documents also state that there is currently insufficient reliable data available regarding the long-term effects of continuous use.

Q: Is it true that Targifor is only for temporary use?

A: The authorized use of Targifor is indicated for states of general asthenia (weakness) and physical fatigue. Official reviews of the active substance, L-Arginine, focus on and are commonly conducted in the context of short-term use.

Q: Are there different forms of Targifor, like tablets vs. ampoules?

A: The officially recognized pharmaceutical forms of Targifor typically include effervescent tablets, an oral solution, or granules that are mixed into a drink. Official product monographs do not list injectable forms, such as ampoules, for this formulation.

Q: Are allergic reactions to Targifor common?

A: Official regulatory labeling classifies severe allergic reactions, such as anaphylaxis, as a serious adverse reaction. This means that severe allergic responses are not listed among the commonly reported side effects of the drug. However, the use of the preparation is strictly constrained in cases of known hypersensitivity.

Q: Are there any known issues with taking Targifor before surgery?

A: Regulatory information advises caution related to surgical procedures. Official guidance suggests that patients may be advised to discontinue the use of L-Arginine products for at least two weeks beforehand. This precaution is based on the potential for the active substance to influence blood clotting and blood pressure levels.

Q: Is Targifor available without a prescription?

A: The product’s classification can vary by region. The specific regulatory status—whether it is available by prescription only or sold over-the-counter—is determined by the local regulatory authority in the country where it is sold.

Q: How long does it typically take to feel an effect from Targifor?

A: Data gathered from clinical studies suggest that a response may be observed within a period of a few days to one week. Research also indicates that the full range of effects may require sustained, regular use over a period of up to three months.

Q: Can Targifor cause difficulty sleeping?

A: Official regulatory documents which detail the medicine's safety profile do not list difficulty sleeping, such as insomnia, as a commonly reported adverse effect.

Q: Does Targifor contain sugar or artificial sweeteners?

A: Yes, certain inactive ingredients are often included in oral formulations. The excipients used in different forms, such as effervescent tablets, may include common sweeteners like Aspartame or various types of sugars such as Dextrose.

Q: Can Targifor interact with herbal supplements?

A: Interactions are possible based on the product’s mechanism. Because Targifor affects both blood pressure and blood clotting, it may interact with herbal supplements that share similar pharmacological effects, such as those intended to lower blood pressure or thin the blood.

Q: Is Targifor a stimulant?

A: According to regulatory classification, Targifor is categorized as an Amino Acid Preparation and a Metabolic Regulator. It is not classified as a central nervous system stimulant.

Q: Can I drive or operate machinery after taking Targifor?

A: Official safety information advises caution. Because the active component, L-Arginine, has been associated with temporary dizziness and lower blood pressure in some individuals, the ability to safely drive or operate heavy machinery may be impacted.

How to Store and Dispose of Targifor

Official regulatory documents define specific storage and disposal requirements to maintain the product's quality and ensure safety.

Required Storage Conditions

Targifor must be stored at a temperature below 25°C (77°F) and should not be frozen. It is mandatory to keep the product protected from light and stored in a dry place to prevent degradation by moisture or humidity. To maintain stability, the preparation must remain in its original container and be closed tightly.

Safety and Disposal

For child safety, all forms of Targifor must be stored out of the sight and reach of children. When disposing of unused or expired medicine, it is mandatory to follow local regulatory requirements for pharmaceutical waste. The product must not be thrown into household waste or wastewater to prevent environmental contamination.